SIM0270

SIM0270 is an investigational agent whose form is not stated in the registry developed by Jiangsu Simcere Pharmaceutical. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, including the phase 3 study NCT06680921 (A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)), in HR-positive / HER2-negative breast cancer. The largest, NCT06680921, plans to enrol 482 participants (actual) with primary completion expected 2028-08-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.